ExpreS2ion to participate in upcoming events
Hørsholm, Denmark, 27 March 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include Swiss Nordic Bio (30 March), a Rights Issue Q&A (31 March), the AACR Annual Meeting (14-19 April) and the Økonomisk Ugebrev Life Science Investor Conference (19 April).
By attending relevant industry and investor events, the company aims to increase the awareness of the ExpreS2 technology platform and its exciting development pipeline, including the novel ES2B-C001 HER2-cVLP breast cancer vaccine. More information on each event and how to register is found below and on the Company’s website.
30 March 2023 | 2023 Swiss Nordic Bio
12:10 CEST | Zurich, Switzerland
CFO Keith Alexander will present ExpreS2ion to investors and potential investors. Registration is possible via the Swiss Nordic Bio website.
31 March 2023 | 2023 Rights Issue Q&A hosted by HC Andersen Capital
13:00 CET | Virtual
ExpreS2ion CEO Bent U. Frandsen and CFO Keith Alexander will discuss the 2023 Rights Issue and answer investors' questions about how to participate. More information and registration can be found on the H.C. Andersen Capital Events website.
16 April 2023 | 2023 American Association of Cancer Research (AACR) Annual Meeting
13:30 EST | Orlando, Florida, USA
ExpreS2ion pre-clinical development partner University of Bologna will present “Preclinical activity of ES2B-C001, a human candidate HER-2 virus-like particle (VLP) vaccine, against mammary carcinoma onset and metastasis.” More information and registration can be found on the AACR website.
19 April 2023 | Økonomisk Ugebrev Life Science Investor Conference
16:45 CET | Copenhagen, Denmark
CEO Bent Frandsen will present ExpreS2ion to investors and potential investors. Registration is possible via the event website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.